• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    2/14/22 4:41:22 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care
    Get the next $XENT alert in real time by email
    SC 13G/A 1 xent-sc13ga_123121.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934*

    (Amendment No. 2)

     
    Intersect ENT Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    46071F103

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☒ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     


    CUSIP No .
    46071F103 Page 2 of 7

     

     

    1

    NAME OF REPORTING PERSONS
    First Light Asset Management, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

    46-3521994

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    0

     
    6

    SHARED VOTING POWER

    1,375,210

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    1,375,210

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,375,210

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.11%

     
    12

    TYPE OF REPORTING PERSON

    IA

     
             

     

     


    CUSIP No .
    46071F103 Page 3 of 7

     

     

             
    1

    NAME OF REPORTING PERSONS
    Mathew P. Arens

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY)

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING POWER

    6,500

     
    6

    SHARED VOTING POWER

    1,375,210

     
    7

    SOLE DISPOSITIVE POWER

    6,500

     
    8

    SHARED DISPOSITIVE POWER

    1,375,210

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,381,710

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.13%

     
    12

    TYPE OF REPORTING PERSON

    IN

     
                             

     

     

     


    CUSIP No .
    46071F103 Page 4 of 7

     

     

     

    Item 1(a).   Name of Issuer:
        Intersect ENT Inc.
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
        1555 Adams Drive, Menlo Park, CA 94025
         
    Item 2(a).   Name of Person Filing:
       

    This Schedule 13G is being jointly filed by the following:

     

    First Light Asset Management, LLC (the “Manager”)

    Mathew P. Arens (“Mr. Arens”)

       

     

    The Manager may be deemed to be the beneficial owner of 1,375,210 of the Issuer’s shares of common stock (the “Shares”). The Manager acts as an investment adviser to certain persons holding separately managed accounts with the Manager, each of whom has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, those shares. The Manager may also be deemed to be the beneficial owner of these shares because it acts as an investment adviser to certain private funds. Mr. Arens may also be deemed to be the beneficial owner of these shares because he controls the Manager in his position as managing member and majority owner of the Manager. Mr. Arens also directly holds 6,500 Shares in an individual capacity with sole control. The Manager and Mr. Arens are filing this Schedule 13G/A with respect to these Shares pursuant to Rule 13d-1(b) under the Act.

     

    The Manager and Mr. Arens may be deemed to be the beneficial owner of the total amount of Shares set forth across from its or his respective name in Item 4 below. The filing of this Schedule 13G shall not be construed as an admission that the reporting persons or any of their affiliates are the beneficial owner of any securities covered by this Schedule 13G for any other purposes other than Section 13(d) of the Securities Exchange Act of 1934.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
       

    Each of the reporting persons identified in Item 2(a) has its principal business office at:

     

    3300 Edinborough Way, Suite 201, Edina, MN 55435

         
    Item 2(c).   Citizenship:
       

    First Light Asset Management, LLC – Delaware limited liability company

    Mathew P. Arens – United States citizen

         
    Item 2(d).   Title of Class of Securities:
        Common Stock, $0.01 par value
         
    Item 2(e).   CUSIP Number:
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     


    CUSIP No .
    46071F103 Page 5 of 7

     

     

           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☒ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
       

    First Light Asset Management, LLC – 1,375,210

    Mathew P. Arens – 1,381,710

         
      (b) Percent of class:
       

    First Light Asset Management, LLC – 4.11%

    Mathew P. Arens – 4.13%

     
         
      (c) Number of shares as to which such person has:
         
        (i) Sole power to vote or to direct the vote
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 6,500

           
        (ii) Shared power to vote or to direct the vote
         

    First Light Asset Management, LLC – 1,375,210

    Mathew P. Arens – 1,375,210

           
        (iii) Sole power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 0

    Mathew P. Arens – 6,500

           
        (iv) Shared power to dispose or to direct the disposition of
         

    First Light Asset Management, LLC – 1,375,210

    Mathew P. Arens – 1,375,210

                 

     

     

     


    CUSIP No .
    46071F103 Page 6 of 7

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

         
     

    FIRST LIGHT ASSET MANAGEMENT, LLC

     

    Date: February 14, 2022

     
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
     

     

    Date: February 14, 2022

     
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  
         

     

     

     


    CUSIP No .
    46071F103 Page 7 of 7

     

     

     

    Exhibit A

    JOINT FILING AGREEMENT

     

     

    The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Intersect ENT Inc, dated as of February 14, 2022, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

         
     

    FIRST LIGHT ASSET MANAGEMENT, LLC

     
       
      By: /s/ Kurt T. Peterson  
      Name: Kurt T. Peterson  
      Title: Chief Compliance Officer  
       
     
      Signature: /s/ Mathew P. Arens  
      Name: Mathew P. Arens  
         

     

     

     

    Get the next $XENT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENT

    DatePrice TargetRatingAnalyst
    8/12/2021$28.25Outperform → Market Perform
    SVB Leerink
    8/10/2021Buy → Neutral
    BTIG
    8/9/2021$29.00 → $28.25Buy → Hold
    Canaccord Genuity
    8/9/2021$28.25Buy → Neutral
    Guggenheim
    6/24/2021$21.00 → $23.00Market Perform → Outperform
    SVB Leerink
    More analyst ratings

    $XENT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hattangadi Neil A

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:58:08 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Meier Richard A closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:43:33 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fernandez Reyna M closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:41:18 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SINUVA issued to INTERSECT ENT INC

    Submission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling

    1/23/23 11:02:41 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    SEC Filings

    View All

    SEC Form POSASR filed by Intersect ENT Inc.

    POSASR - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 5:25:28 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form RW WD filed by Intersect ENT Inc.

    RW WD - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 1:10:59 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by Intersect ENT Inc.

    15-12B - Intersect ENT, Inc. (0001271214) (Filer)

    5/23/22 6:08:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

    Current President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the

    7/14/22 12:05:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

    Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist, ER/urgent care and outpatient visits, as well as sinus-related endoscopies Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps

    1/25/22 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intersect ENT downgraded by SVB Leerink with a new price target

    SVB Leerink downgraded Intersect ENT from Outperform to Market Perform and set a new price target of $28.25

    8/12/21 4:49:01 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by BTIG

    BTIG downgraded Intersect ENT from Buy to Neutral

    8/10/21 5:09:28 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Intersect ENT from Buy to Hold and set a new price target of $28.25 from $29.00 previously

    8/9/21 10:22:16 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Financials

    Live finance-specific insights

    View All

    Intersect ENT Reports Third Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp

    11/2/21 4:15:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Reports Second Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm

    8/6/21 7:15:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may

    7/23/21 8:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/23/22 8:56:48 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/17/22 11:40:20 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/14/22 4:41:22 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Announces Appointment of New Vice President of Sales

    Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005421/en/Mark L. Alley (Photo: Business Wire) Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 compan

    5/4/21 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care